Skip to main content

Dr. Charles Leath

Gynecologic Oncology (Gynecologic Oncology Physician)

  • Medicare participating

At a glance

Years since graduation
28
In the NPI registry since
2005
Medicare patients seen, 2024
140

Licensed in Alabama since 1999, according to the Alabama Board of Medical Examiners and Medical Licensure Commission. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Gynecologic Oncology Physician primary
    AL license 22823 (first issued 1999; active)

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Gynecologic Oncology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
140
Services billed
454
Patients’ average age
69
Most frequent Medicare services, 2023
ServiceTimesPatients
Established patient office or other outpatient visit, 40-54 minutes13461
Established patient office or other outpatient visit, 30-39 minutes6858
Established patient office or other outpatient visit, 20-29 minutes4743
New patient office or other outpatient visit, 60-74 minutes1414

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 6 companies reported 22 payments worth $48,690 in total to this clinician.

By company
Merck Sharp & Dohme LLC$37,517
GlaxoSmithKline, LLC.$5,290
Genmab U.S., Inc.$3,200
AbbVie Inc.$2,453
Caris Mpi, Inc.$213
Medical Device Business Services, Inc.$18.19
By type
Compensation for services other than consulting (speaking, faculty)$19,840
Travel and Lodging$17,330
Consulting Fee$10,800
Food and Beverage$720

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Nov 18, 2025Merck Sharp & Dohme LLC
Nov 18, 2025
Travel and Lodging
travel to Sydney, Australia · in-kind
$15,461
Dec 8, 2025Merck Sharp & Dohme LLC
Dec 8, 2025
Compensation for services other than consulting (speaking, faculty)$12,160
Apr 21, 2025Merck Sharp & Dohme LLC
Apr 21, 2025
Compensation for services other than consulting (speaking, faculty)$7,680
Jul 25, 2025Genmab U.S., Inc.
Jul 25, 2025
Consulting Fee
Epkinly · Oncology · in-kind
$3,200
Sep 4, 2025GlaxoSmithKline, LLC.
Sep 4, 2025
Consulting Fee
JEMPERLI · ONCOLOGY
$2,800
Sep 26, 2025AbbVie Inc.
Sep 26, 2025
Consulting Fee
ELAHERE · ONCOLOGY
$2,400
May 22, 2025GlaxoSmithKline, LLC.
May 22, 2025
Consulting Fee
JEMPERLI · ONCOLOGY
$2,400
Nov 18, 2025Merck Sharp & Dohme LLC
Nov 18, 2025
Travel and Lodging
travel to Sydney, Australia · in-kind
$1,066
Nov 18, 2025Merck Sharp & Dohme LLC
Nov 18, 2025
Travel and Lodging
travel to Sydney, Australia · in-kind
$478
Dec 8, 2025Merck Sharp & Dohme LLC
Dec 8, 2025
Travel and Lodging
travel to Sydney, Australia
$150
All 12 payments other than meals, newest first
All payments other than meals
DateCompanyWhat it was forAmount
Dec 8, 2025Merck Sharp & Dohme LLC
Dec 8, 2025
Compensation for services other than consulting (speaking, faculty)$12,160
Dec 8, 2025Merck Sharp & Dohme LLC
Dec 8, 2025
Travel and Lodging
travel to Sydney, Australia
$150
Nov 18, 2025Merck Sharp & Dohme LLC
Nov 18, 2025
Travel and Lodging
travel to Sydney, Australia · in-kind
$15,461
Nov 18, 2025Merck Sharp & Dohme LLC
Nov 18, 2025
Travel and Lodging
travel to Sydney, Australia · in-kind
$1,066
Nov 18, 2025Merck Sharp & Dohme LLC
Nov 18, 2025
Travel and Lodging
travel to Sydney, Australia · in-kind
$478
Sep 26, 2025AbbVie Inc.
Sep 26, 2025
Consulting Fee
ELAHERE · ONCOLOGY
$2,400
Sep 4, 2025GlaxoSmithKline, LLC.
Sep 4, 2025
Consulting Fee
JEMPERLI · ONCOLOGY
$2,800
Jul 25, 2025Genmab U.S., Inc.
Jul 25, 2025
Consulting Fee
Epkinly · Oncology · in-kind
$3,200
Jun 1, 2025Merck Sharp & Dohme LLC
Jun 1, 2025
Travel and Lodging
KEYTRUDA · ONCOLOGY · travel to Chicago, IL
$26.08
May 22, 2025GlaxoSmithKline, LLC.
May 22, 2025
Consulting Fee
JEMPERLI · ONCOLOGY
$2,400
Apr 21, 2025Merck Sharp & Dohme LLC
Apr 21, 2025
Compensation for services other than consulting (speaking, faculty)$7,680
Apr 21, 2025Merck Sharp & Dohme LLC
Apr 21, 2025
Travel and Lodging
travel to Bangkok, Thailand
$150

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Alabama →

Industry-funded research

Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $63,793 in research payments for these studies, mostly to the institutions running them.

  • A phase 1 dose escalation and cohort expansion study of TSR-042, an an
    GlaxoSmithKline, LLC.
  • First in Human Study of IMGN151 in Recurrent Gynaecological Cancers
    AbbVie Inc. · Active, not recruiting · NCT05527184
  • A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With or Without Radiotherapy for the Treatment of Newly Diagnosed High-Risk Endometrial Cancer After …
    Merck Sharp & Dohme LLC

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Gynecologic Oncology clinicians in Birmingham

Sources

NPI registry (CMS NPPES, November 2026; record last updated February 1, 2024), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1255313193. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.